Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Pro

[1]  Kirsten L. Greene,et al.  Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging , 2021, The Journal of Nuclear Medicine.

[2]  F. Saad,et al.  Treatment and trials in non-metastatic castration-resistant prostate cancer , 2021, Nature reviews. Urology.

[3]  N. Bander,et al.  Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer , 2021, Frontiers in Oncology.

[4]  L. Livi,et al.  Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy , 2021, Clinical and Translational Oncology.

[5]  R. Jeraj,et al.  Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sean S. Park,et al.  Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer , 2020, International journal of radiation oncology, biology, physics.

[7]  M. Zelefsky,et al.  Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. , 2020, Journal of the National Cancer Institute.

[8]  S. Freedland,et al.  A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration , 2020, Clinical Cancer Research.

[9]  Sean S. Park,et al.  Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. , 2020, European urology oncology.

[10]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[11]  John F. Trant,et al.  Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for 18F-FDG Imaging of PSMA-Suppressed Tumors , 2019, The Journal of Nuclear Medicine.

[12]  L. Lacombe,et al.  Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. , 2019, European urology focus.

[13]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[14]  T. Takahara,et al.  Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor. , 2019, International journal of radiation oncology, biology, physics.

[15]  K. Haustermans,et al.  Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. , 2019, European urology oncology.

[16]  F. Saad,et al.  Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer , 2019, Clinical Cancer Research.

[17]  D. Song,et al.  Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. , 2019, European urology.

[18]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[19]  M. Scorsetti,et al.  Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study , 2019, World Journal of Urology.

[20]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[21]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[22]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[23]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[24]  H. Hieronymus,et al.  Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors , 2018, The Journal of experimental medicine.

[25]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Groshen,et al.  Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[27]  A. D'Amico,et al.  Prostate Specific Antigen Doubling Time , 2008 .

[28]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.